ABBV · Categories · Upgrades
ABBV - Analyst upgrades
AbbVie Inc. (ABBV) analyst upgrades - real-time wire coverage filtered to Upgrades only.
Recent Upgrades for ABBV
- AbbVie upgraded by BofA Securities with a new price targetBofA Securities upgraded AbbVie from Neutral to Buy and set a new price target of $234.00
- AbbVie upgraded by HSBC Securities with a new price targetHSBC Securities upgraded AbbVie from Hold to Buy and set a new price target of $265.00
- AbbVie upgraded by Berenberg with a new price targetBerenberg upgraded AbbVie from Hold to Buy and set a new price target of $270.00
- AbbVie upgraded by Daiwa Securities with a new price targetDaiwa Securities upgraded AbbVie from Neutral to Outperform and set a new price target of $214.00
- AbbVie upgraded by Leerink Partners with a new price targetLeerink Partners upgraded AbbVie from Market Perform to Outperform and set a new price target of $206.00
- AbbVie upgraded by ArgusArgus upgraded AbbVie from Hold to Buy
- AbbVie upgraded by HSBC Securities with a new price targetHSBC Securities upgraded AbbVie from Hold to Buy and set a new price target of $185.00
- AbbVie upgraded by William BlairWilliam Blair upgraded AbbVie from Mkt Perform to Outperform
- AbbVie upgraded by GoldmanGoldman upgraded AbbVie from Neutral to Buy
- AbbVie upgraded by Barclays with a new price targetBarclays upgraded AbbVie from Equal Weight to Overweight and set a new price target of $170.00 from $160.00 previously
- AbbVie upgraded by SVB Securities with a new price targetSVB Securities upgraded AbbVie from Underperform to Market Perform and set a new price target of $153.00 from $135.00 previously
- AbbVie upgraded by Societe Generale with a new price targetSociete Generale upgraded AbbVie from Hold to Buy and set a new price target of $172.00